Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2019-12-10 Regulatory Filings
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an update on a clinical trial enrollment (MAESTRO-NAFLD-1) and includes forward-looking statements. There are no financial statements or detailed financial performance data present. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing to inform investors of a material event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 6425 characters, which is sufficient for a substantive filing but does not contain financial data to classify as a financial report type.
2019-12-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2019, reporting the company's financial results for the first fiscal quarter ended September 30, 2019. It specifically states that the company issued a press release announcing these results, and the press release is furnished as an exhibit. The document itself is a current report providing an update on earnings results, not a full quarterly report with detailed financial statements. The length is 3635 characters, which is relatively short and consistent with an earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER).
2019-11-06 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-06 English
SC 13D/A
Major Shareholding Notification
2019-10-17 English
SC 13D/A
Major Shareholding Notification
2019-10-17 English
SC 13D/A
Major Shareholding Notification
2019-10-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.